Barry W. Feig, MD

Articles

Irinotecan/Cisplatin in Advanced, Treated Gastric or Gastroesophageal Junction Carcinoma

Jaffer A. Ajani, MD;Jackie Baker, RN;Peter W. T. Pisters, MD;Linus Ho, MD, PhD;Paul F. Mansfield, MD;Barry W. Feig, MD;Chulsip Charnsangavej, MD

May 2nd 2002

We conducted a phase II study to assess the response rate and toxicity profile of the irinotecan (CPT-11, Camptosar) plus cisplatin combination administered weekly to patients with at least one previous chemotherapy for advanced adenocarcinoma of the stomach or gastroesophageal junction. Patients with histologic proof of adenocarcinoma of the stomach or gastroesophageal junction with adequate liver, kidney, and bone marrow functions were treated with 50 mg/m² of irinotecan plus 30 mg/m² of cisplatin, both administered intravenously 1 day a week for 4 consecutive weeks, followed by a 2-week recovery period.

Irinotecan Plus Cisplatin in Advanced Gastric or Gastroesophageal Junction Carcinoma

Jaffer A. Ajani, MD;Jackie Baker, RN;Peter W. T. Pisters, MD;Linus Ho, MD, PhD;Barry W. Feig, MD;Paul F. Mansfield, MD

March 2nd 2001

A phase II study was conducted to assess the response rate and toxicity profile of the combination of irinotecan (CPT-11, Camptosar) and cisplatin (Platinol) administered weekly to patients with untreated advanced

Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors

Ritsuko Komaki, MD;Nora A. Janjan, MD;Jaffer A. Ajani, MD;Patrick M. Lynch, MD;Jackie S. Fairweather, RN;Isaac Raijman, MD;George R. Blumenshein, MD;Linus Ho, MD, PhD;Peter W. T. Pisters, MD;Barry W. Feig, MD;Garrett L. Walsh, MD;Richard Pazdur, MD

December 3rd 2000

Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly